Literature DB >> 8835358

Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors.

O Hustveit1, A Maurset, I Oye.   

Abstract

In order to elucidate the mechanisms of action of ketamine, we have investigated the binding of the chiral forms of ketamine to opioid (mu, delta and kappa), phencyclidine, sigma and muscarinic receptors and we have performed detailed concentration-response experiments in the guinea-pig ileum preparation. The affinity ratios for the chiral forms at phencyclidine, mu and kappa receptors correlated with the potency ratio of the chiral forms in the ischaemic pain test found previously. The affinities were highest for phencyclidine receptors. The affinities for muscarinic receptors were lower than for phencyclidine receptors by a factor of about 10-20. The concentration-response experiments revealed one opioid (naloxone sensitive) and one non-opioid component. The two component are very close, which explains why other authors have reported that naloxone antagonizes the ketamine effect only partly. The concentrations of naloxone necessary to shift the opioid part of the curves indicate that ketamine is a kappa agonist in the guinea-pig ileum preparation. We conclude that the analgesic effect of ketamine in humans is most probably mediated via phencyclidine receptors, although a kappa effect can not be excluded. Binding to kappa and muscarinic receptors may contribute to the psychotomimetic side effects seen during recovery from ketamine anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8835358     DOI: 10.1111/j.1600-0773.1995.tb01041.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  45 in total

1.  Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents.

Authors:  Rose Schnoebel; Matthias Wolff; Saskia C Peters; Michael E Bräu; Andreas Scholz; Gunter Hempelmann; Horst Olschewski; Andrea Olschewski
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Reply to: Rapid antidepressant effects and abuse liability of ketamine.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-05       Impact factor: 4.530

3.  The Epidural and Intrathecal Administration of Ketamine.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

4.  The effect of target-controlled infusion of low-dose ketamine on heat pain and temporal summation threshold.

Authors:  Joon-Ho Lee; Sung-Hwan Cho; Sang-Hyun Kim; Won-Soek Chae; Hee-Cheol Jin; Jeong-Seok Lee; Yong-Ik Kim
Journal:  J Anesth       Date:  2011-04-22       Impact factor: 2.078

5.  The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents.

Authors:  Adam L Halberstadt; Natalia Slepak; James Hyun; Mahalah R Buell; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2016-01-13       Impact factor: 4.530

Review 6.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 7.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

8.  Additive and subadditive antiallodynic interactions between μ-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys.

Authors:  Jeremy C Cornelissen; Floyd F Steele; Kenner C Rice; Katherine L Nicholson; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

9.  Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations.

Authors:  James W Murrough
Journal:  Psychopharmacology (Berl)       Date:  2015-03-11       Impact factor: 4.530

10.  A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Authors:  Jerry J Buccafusco; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2009-07-03       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.